Michael Burgess

Michael M.
Burgess currently works at The Royal College of Physicians, as Member, The Royal College of Paediatrics & Child Health, as Member, and iOmx Therapeutics AG, as Member-Supervisory Board from 2022.
Dr. Burgess also formerly worked at Turnstone Biologics Corp., as Director from 2024 to 2025, Synlogic, Inc., as Independent Director from 2020 to 2024, Bristol Myers Squibb Co., as SVP-Discovery Medicine & Clinical Pharmacology, Roche Holding AG, as Head-Oncology Discovery & Translational Area in 2012, Hoffmann-La Roche, Inc., as Global Head-DTA Oncology Division, Roche Holding (UK) Ltd., as Head-Clinical Research Division in 2010, Roche Ltd., as Head-Oncology Discovery & Translational Area, and Springworks Therapeutics, Inc., as Head-Research & Development from 2021 to 2022.
Dr. Burgess received his graduate degree in 1989 from the University of Bristol and doctorate degree in 1999 from the University of Bristol.